Wells Fargo has downgraded Merus NV (MRUS) from Overweight to Equal-Weight, reflecting a more cautious outlook for the biotechnology firm. The action, taken on September 28, 2025, comes as Merus navigates competitive pressures and potential execution risks that could impact its performance.
Merus NV, headquartered in Utrecht, Netherlands, is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics. The company employs 260 full-time staff and went public on May 19, 2016. Its pipeline includes products designed to engage cancer antigens and utilize the immune system to target tumor cells. One notable drug in development is zenocutuzumab (Zeno), aimed at treating patients with lung, pancreatic, and other solid tumors.
As of November 20, 2025, Merus has a market capitalization of $7.3 billion and an earnings per share (EPS) of -5.34. The company's upcoming earnings reports are anticipated, with estimates for August 3, 2026, projecting an EPS of -1.40 and revenue of $10.8 million.
Analyst ratings can fluctuate as new data emerges. Currently, the analyst consensus for Merus NV stands at 3 Strong Buy, 6 Buy, and 14 Hold ratings, indicating a general preference for caution among analysts following recent downgrades from several firms, including Truist Securities and Citigroup, on the same day as Wells Fargo's action.
This update provides insight into the evolving sentiment surrounding Merus NV, as analysts weigh the company's fundamentals against the backdrop of an uncertain market environment.